blackjack3d / iStockphoto.com
23 January 2018Americas
Sanofi to buy Bioverativ for $11.6bn
Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.
Europe
19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Americas
5 March 2020 Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.
Editor's picks
Editor's picks
Americas
19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.
Europe
19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Americas
5 March 2020 Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.
Americas
19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.
Europe
19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Americas
5 March 2020 Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.